Literature DB >> 6354437

Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.

A Ramu, T C Shan, D Glaubiger.   

Abstract

Acquired resistance to doxorubicin in a P388 murine leukemia cell subline was found to be associated with decreased drug accumulation in these cells. We have previously shown that the lipid domain of the plasma membrane in drug-resistant cells is structurally more ordered and has a lower phosphatidylcholine/sphingomyelin ratio. Perhexiline maleate and triparanol both markedly enhance the sensitivity of drug-resistant cells to doxorubicin and vinblastine but do not have an effect on anthracycline-sensitive cells. This enhanced sensitivity is associated with increased drug accumulation. Although perhexiline maleate has been reported to be a calcium antagonist in other systems, our data do not implicate this mechanism in the enhancement of cell sensitivity to doxorubicin. We suggest that this effect might be related to alterations of the cell membrane lipid domain induced by perhexiline maleate and triparanol, which result in decreased structural order of plasma membrane lipids and permit increased drug accumulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354437

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells.

Authors:  P Gros; J Croop; I Roninson; A Varshavsky; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

3.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  V Wiebe; S Koester; M Lindberg; V Emshoff; J Baker; G Wurz; M DeGregorio
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

6.  Targeting chemosensitizing doses of toremifene based on protein binding.

Authors:  G T Wurz; V D Emshoff; M W DeGregorio; V J Wiebe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.

Authors:  B J Foster; K R Grotzinger; W M McKoy; L V Rubinstein; T C Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain.

Authors:  A M Van der Bliek; M B Meyers; J L Biedler; E Hes; P Borst
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

9.  A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.

Authors:  C M West; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  5'-Nucleotidase activity and arachidonate metabolism in doxorubicin sensitive and resistant P388 cells.

Authors:  A Ramu; D Glaubiger; P Soprey; G H Reaman; N Feuerstein
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.